Search

Objectives Liver cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. HCV is one of the major causes of liver fibrosis and ultimate progression to cirrhosis. Transforming growth factor-beta1 (TGF-β1), one of the three isoforms of TGF-β, is a pleiotrophic cytokine that regulates the proliferation and differentiation of cells, embryonic development, wound healing and angiogenesis. This study aimed to evaluate the role of serum TGF-β1 and − 509 C>T promoter gene polymorphism in the development of liver cirrhosis. Design and methods Besides routine liver profiles, serum TGF-β1 was measured in 40 liver cirrhosis patients and 40 controls using ELISA technique. TGF-β1 − 509 C>T promoter gene polymorphism was detected using PCR-RFLP technique. Results TGF-β1 − 509 CT and TT genotype frequencies were significantly higher in the cirrhotic group (52.5%, 25%; respectively) than control group (10%, 7.5%; respectively); OR = 16.238 (95% CI 5.391–48.914, p

The present study aimed at evaluating the role of IL-1β −511 promoter and IL-1β +3953 exon 5 gene polymorphisms in the risk of developing rheumatoid arthritis (RA) and its correlation to disease activity in Egyptian patients. Thirty-two patients having RA as defined by American College of Rheumatology and 20 healthy control subjects were included. All were subjected to DNA analysis for IL-1β −511and IL-1β +3953 gene polymorphisms using PCR-RFLP technique with restriction enzymes AvaI and TaqI, respectively. No special pattern of association could be detected either between IL-1β −511 and +3953 gene polymorphisms and disease susceptibility or between the polymorphisms and the disease activity parameters represented by disease activity score 28 (DAS 28), ESR, and number of swollen and tender joints. Allele distribution failed as well to detect any association with either disease susceptibility or activity; however, a trend towards positive association involving IL-1β −511 C allele was observed (P = 0.054). Our results suggest that IL-1β −511 and IL-1β +3953 gene polymorphisms do not influence the susceptibility to acquire RA in our population with no relation to disease activity. The complex role of the genetic factors in RA and the magnitude of the effects will require further thorough confirmations in other populations and on larger samples to acknowledge this issue.

Asthma is a multifactorial respiratory disease determined by interactions of multiple disease susceptibility genes and environmental factors. Interleukin (IL)-18 is an important cytokine for initiating and perpetuating the catabolic and inflammatory response in allergic asthma. A number of single nucleotide polymorphisms that influence IL-18 production are found in the gene promoter region. The aim of this study was to investigate the association of IL-18 −607C/A promoter polymorphism with asthma and whether this polymorphism influenced the severity of asthma in affected children. The influence of this promoter gene polymorphism on total serum IgE level in studied subjects was also investigated. This study was carried out at the Allergy Clinic of Abu El Reesh Children’s Hospital at Cairo University, Egypt. This study included 40 asthmatic children, subdivided into four groups according to different degrees of asthma severity, and 20 apparently healthy subjects as the control group. All cases were subjected to history taking, clinical examination, and the following laboratory investigations: complete blood count, total serum IgE level assay by ELISA and genomic DNA extraction, and analysis for IL-18 −607C/A promoter gene polymorphism using the PCR-RFLP (restriction fragment length polymorphism) technique. In the present study the IL-18 −607AA genotype frequency was higher in cases (22.5 %) than in the control group (15 %); however, the difference was not statistically significant (p = 0.773). No statistically significant difference between the degree of asthma severity and IL-18 −607C/A polymorphism was found (p = 0.489). No significant association could be detected upon comparing the frequencies of C and A alleles among the two studied groups (p = 0.366). Also, no significant differences were demonstrated for the allele frequencies when the intermittent with mild [odds ratio (OR) = 2.72, 95 % CI 1.03–2.33, p = 0.067], intermittent with moderate, and severe (OR = 2.8, 95 % CI 1.01–8.5, p = 0.066) asthma groups were compared. The median value of the total serum IgE level in asthmatic cases with the mutant genotype (AA) was significantly higher [360 IU/L (96.6–1,340 IU/L)] than in the control group [119 IU/L (70.6–158.9 IU/L)] (p = 0.033). No significant statistical difference was encountered regarding the distribution of IL-18 −607C/A genotypes and allele frequencies in asthma patients and healthy controls. Also, there were no significant associations between asthma severity and different genotypes or alleles. The median value of the total serum IgE level in asthmatic cases with the mutant genotype (AA) was significantly higher than in the control group. Thus, IL-18 −607AA genotype frequency might be related to higher total serum IgE.